Capital TECHNOLOGY

Non-Invasive Prenatal Testing (NIPT) for Fetal Aneuploidies (Trisomy 21, Trisomy 18 and Trisomy 13)

Accurate • Early • Safe • Rapid

Background

Chromosomal disorders are diseases caused by abnormalities in the number or structure of chromosomes, with trisomy 21, trisomy 18, and trisomy 13 being relatively common in clinical practice. Most of pediatric patients with these conditions exhibit intellectual disabilities, developmental delays, and multiple congenital anomalies, etc., and most cannot live independently. There are no effective treatment methods currently available.

Prenatal screening and diagnosis are crucial for preventing chromosomal abnormalities, which should be paid attention to by every family. Adhere to early detection, early diagnosis, and early intervention to avoid the occurrence of tragedies.



Product Introduction

NIPT is a safe, accurate, and rapid technology for detecting fetal chromosomal abnormalities. It not only demonstrates a significantly higher accuracy than other prenatal screening methods and is close to that of prenatal diagnosis, but also has the advantage of being non-invasive, making it an essential complement to current prenatal diagnostic technology system.

NIPT of CapitalBio Technology, based on high throughput sequencing technology, analyzes the concentration of cell free fetal DNA (cffDNA) in maternal plasma to determine the risk of fetal chromosomal aneuploidies (trisomy 21, trisomy 18, and trisomy 13) accurately, safely, early and rapidly.



Product Features

Accurate test

Patented cffDNA enrichment technology improving fetal fraction

Accurate result

Validated sensitivity and specificity >99%

High efficiency

Simple workflow with minimum hands-on time and cost

Automated interpretation

Self-developed algorithm and analysis system

Applicable Population

- Pregnant women with serum screening results indicating that the risk value of fetal autosomal aneuploidies is between the high-risk cut-off value and 1/1000;
- Pregnant women with contraindications for invasive prenatal diagnosis (such as with warning signs of miscarriage, with fever, with bleeding tendency, in the active phase of chronic infection, with Rh-negative blood type, etc.);
- Women who are more than 20^{+6} weeks pregnant , have missed the optimal time for serum screening, but require assessment of the risk of trisomy 21, trisomy 18, and trisomy 13.

Instrument Platform and Kitted Reagents



CBTSeq2 Pro Genetic Sequencer

Fetal Aneuploidies (Trisomy 21, Trisomy 18 and Trisomy 13) Detection Kit (Reversible Termination Sequencing)

CapitalBiotech

Add: Building C, Yizhuang Biomedical Park, No. 88, Kechuang Sixth Street, Beijing Economic-Technological Development Area, Beijing 101111, China
Website: www.capitalbiotechnology.com Tel: +86-10-69002900 E-Mail: globalsales@capitalbiotech.com